Gil Blum
Stock Analyst at Needham
(4.36)
# 1,343
Out of 5,136 analysts
727
Total ratings
35.9%
Success rate
9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gil Blum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Reiterated: Buy | $9 | $2.16 | +316.67% | 53 | Nov 13, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $82 | $40.37 | +103.12% | 45 | Nov 10, 2026 | |
| ARTV Artiva Biotherapeutics | Downgraded: Hold | n/a | $3.96 | - | 18 | Oct 27, 2026 | |
| RXRX Recursion Pharmaceuticals | Reiterated: Buy | $8 | $2.91 | +175.39% | 31 | Oct 19, 2026 | |
| FATE Fate Therapeutics | Reiterated: Hold | n/a | $1.14 | - | 25 | Oct 5, 2026 | |
| NKTX Nkarta | Reiterated: Buy | $11 | $1.21 | +809.09% | 24 | Oct 5, 2026 | |
| AUTL Autolus Therapeutics | Reiterated: Buy | $10 | $1.14 | +777.19% | 53 | Oct 2, 2026 | |
| CELC Celcuity | Reiterated: Buy | $140 → $134 | $60.57 | +121.23% | 35 | Sep 30, 2026 | |
| IMMX Immix Biopharma | Reiterated: Buy | $21 → $30 | $7.48 | +301.07% | 3 | Sep 29, 2026 | |
| RNAC Cartesian Therapeutics | Reiterated: Buy | $40 | $6.08 | +557.89% | 38 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $15.13 | - | 57 | Sep 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 | $7.48 | +47.16% | 15 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $44 | $14.65 | +200.34% | 7 | Sep 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.1451 | - | 19 | Sep 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $56 | $9.28 | +503.45% | 1 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $4.06 | +195.57% | 50 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $3 | $0.305 | +883.61% | 35 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $6.48 | +193.21% | 8 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $28.88 | +159.70% | 23 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $0.9419 | +324.67% | 36 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $34 | $14.73 | +130.82% | 48 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.66 | n/a | 28 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.7915 | n/a | 25 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.68 | n/a | 15 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $20.98 | n/a | 14 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $99.37 | n/a | 10 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.000001 | n/a | 6 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 | $0.000001 | n/a | 5 | Apr 6, 2022 |
Rocket Pharmaceuticals
Nov 13, 2026
Reiterated: Buy
Price Target: $9
Current: $2.16
Upside: +316.67%
CRISPR Therapeutics AG
Nov 10, 2026
Reiterated: Buy
Price Target: $82
Current: $40.37
Upside: +103.12%
Artiva Biotherapeutics
Oct 27, 2026
Downgraded: Hold
Price Target: n/a
Current: $3.96
Upside: -
Recursion Pharmaceuticals
Oct 19, 2026
Reiterated: Buy
Price Target: $8
Current: $2.91
Upside: +175.39%
Fate Therapeutics
Oct 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.14
Upside: -
Nkarta
Oct 5, 2026
Reiterated: Buy
Price Target: $11
Current: $1.21
Upside: +809.09%
Autolus Therapeutics
Oct 2, 2026
Reiterated: Buy
Price Target: $10
Current: $1.14
Upside: +777.19%
Celcuity
Sep 30, 2026
Reiterated: Buy
Price Target: $140 → $134
Current: $60.57
Upside: +121.23%
Immix Biopharma
Sep 29, 2026
Reiterated: Buy
Price Target: $21 → $30
Current: $7.48
Upside: +301.07%
Cartesian Therapeutics
Sep 29, 2026
Reiterated: Buy
Price Target: $40
Current: $6.08
Upside: +557.89%
Sep 28, 2026
Reiterated: Sell
Price Target: n/a
Current: $15.13
Upside: -
Sep 23, 2026
Reiterated: Buy
Price Target: $11
Current: $7.48
Upside: +47.16%
Sep 11, 2026
Reiterated: Buy
Price Target: $44
Current: $14.65
Upside: +200.34%
Sep 2, 2026
Downgraded: Hold
Price Target: n/a
Current: $0.1451
Upside: -
Aug 21, 2026
Initiated Coverage: Buy
Price Target: $56
Current: $9.28
Upside: +503.45%
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $4.06
Upside: +195.57%
Aug 11, 2026
Reiterated: Buy
Price Target: $3
Current: $0.305
Upside: +883.61%
Aug 7, 2026
Reiterated: Buy
Price Target: $19
Current: $6.48
Upside: +193.21%
Aug 6, 2026
Reiterated: Buy
Price Target: $75
Current: $28.88
Upside: +159.70%
Aug 5, 2026
Reiterated: Buy
Price Target: $4
Current: $0.9419
Upside: +324.67%
Aug 4, 2026
Reiterated: Buy
Price Target: $34
Current: $14.73
Upside: +130.82%
Nov 7, 2025
Reiterated: Hold
Price Target: n/a
Current: $4.66
Upside: n/a
Oct 24, 2025
Rated: Hold
Price Target: n/a
Current: $0.7915
Upside: n/a
Dec 27, 2024
Rated: Hold
Price Target: n/a
Current: $6.68
Upside: n/a
Dec 7, 2022
Reiterated: Buy
Price Target: $6
Current: $20.98
Upside: n/a
Aug 25, 2022
Rated: Hold
Price Target: n/a
Current: $99.37
Upside: n/a
Jun 3, 2022
Rated: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Apr 6, 2022
Reiterated: Buy
Price Target: $6
Current: $0.000001
Upside: n/a